Detrovel

Simvastatin

Method of action: Hypocholesterolemic, Inhibiting Hmg-Coa Reductase, Lipid Modifying Agents, Lipid-Lowering

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Detrovel

Quick Facts

Property	Description
Active ingredient	Simvastatin (INN)
Form	Tablet, Oral suspension
Pharmacological class	HMG-CoA reductase inhibitor (Statin)
General purpose	Lipid-lowering agent
Origin	Semi-synthetic derivative

What Type of Medicine is Detrovel? (Identity and Classification)

Detrovel is a prescription-only medicine whose therapeutic identity is defined by its active ingredient, Simvastatin. It is categorized as an antilipemic agent and belongs to the functional pharmacological class of HMG-CoA reductase inhibitors, commonly known as the statins. This classification emphasizes its specialized function in altering lipid production within the body, a role clinically recognized and supported by extensive pharmacological studies.

The statin designation means Detrovel's primary role is to modify the blood's lipid composition. As a single-ingredient product, it focuses exclusively on reducing the levels of Low-Density Lipoprotein Cholesterol (LDL-C), which is a key goal in managing patients at high risk for vascular events.

Composition and Origin: Simvastatin as a Prodrug

The core chemical component is Simvastatin, a substance derived semi-synthetically from a fermentation product. For the oral route of administration, the drug is typically provided in standard pharmaceutical forms such as the solid tablet and, in some contexts, an oral suspension. The substance itself is a prodrug, meaning the administered inactive form requires metabolic conversion by the liver to become the active chemical that performs the therapeutic function. This initial conversion step is characteristic of this molecule's activity, ensuring targeted action.

What is Detrovel’s General Purpose? (High-Level Benefit)

Detrovel’s general purpose is to act as a powerful lipid-lowering agent to support the management of elevated levels of lipids, known as hyperlipidemia. By controlling the internal synthesis of cholesterol, the drug effectively reduces the concentration of circulating LDL-C and triglycerides. This fundamental therapeutic benefit is essential for cardiovascular disease risk reduction, representing a widely adopted strategy in modern medical guidelines. The medication's ability to achieve a systematic control of adverse lipid levels forms a critical pillar in mitigating the long-term risk associated with the progression of conditions like atherosclerosis.

Regulatory References

Simvastatin Vale - referral | European Medicines Agency (EMA)

What side effects are possible with Detrovel?

Detrovel's safety profile is formally documented by regulatory authorities, with adverse reactions classified by frequency of occurrence, system-organ class, and severity.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on incidence reported in official sources:

Common (e.g., in ge 1% of patients): Includes headache, upper respiratory infection, myalgia (muscle pain), constipation, abdominal pain, and nausea.
Rare (e.g., in ge 0.01% to < 0.1% of patients): Includes myopathy (muscle disease), rhabdomyolysis (severe muscle breakdown), hepatitis, jaundice, and pancreatitis.
Not Known (Cannot be estimated): Includes cognitive impairment, depression, interstitial lung disease, and erectile dysfunction.

Serious Adverse Reactions and Systemic Concerns

The most significant safety concerns explicitly listed in regulatory labeling involve the musculoskeletal and hepatobiliary systems. Rhabdomyolysis is a rare but severe muscle injury that can lead to acute renal failure. Additionally, rare cases of fatal and non-fatal hepatic failure have been reported. Rare apparent hypersensitivity syndromes have also been documented, which may involve symptoms such as vasculitis or angioedema.

Safety-Related Limitations and Constraints

Official documents specify several limitations on the use of Detrovel:

Contraindications: Use is strictly forbidden in patients with active liver disease and in women who are pregnant or breastfeeding. Concomitant use with certain strong CYP3A4 inhibitors (e.g., itraconazole) and other specific drugs (e.g., gemfibrozil, cyclosporine) is also contraindicated due to increased muscle risk.
Dose Risk: The risk of serious muscle injury increases with higher doses. The mathbf80 mg dose is restricted for patients who have already been taking it for mathbf12 months or more without muscle toxicity and should not be started in new patients.
Population Notes: Advanced age (ge 65 years), uncontrolled hypothyroidism, and renal impairment are noted as predisposing factors that increase the risk of myopathy.

The formal regulatory safety information structures the understanding of risks by clearly differentiating between common, non-serious effects and rare, serious muscle and liver disorders, thereby defining necessary restrictions on use and patient screening.

Overdose and Emergency Response

Detrovel Overdose and When to Seek Help

Taking more than the prescribed dose of Detrovel (simvastatin) can lead to serious health issues. An overdose may result in severe muscle damage, a condition known as rhabdomyolysis, which can subsequently cause kidney failure. Additionally, liver function abnormalities may be exacerbated.

Symptoms of a Potential Overdose

While there is no specific symptom profile for Detrovel overdose, signs that may indicate a dangerously high level in the body or a severe reaction include:

Unexplained Muscle Pain, Tenderness, or Weakness: Especially if accompanied by fever or feeling generally unwell.
Dark-colored or Red-brown Urine: A primary sign of rhabdomyolysis.
Yellowing of the Skin or Eyes (Jaundice): Suggests severe liver involvement.
Severe Nausea, Vomiting, or Abdominal Pain.

Immediate Medical Attention

If you suspect an overdose, even if no symptoms are immediately apparent, or if the individual has taken an amount higher than the maximum daily dose (typically 40 mg, though 80 mg is restricted to specific chronic use), seek emergency medical help immediately.

Do not wait for symptoms to worsen. Time is critical in mitigating potential muscle and organ damage. Be prepared to provide the name of the medicine, the amount taken, and the time it was ingested. Treatment often involves monitoring vital signs, blood tests to check muscle and liver enzymes, and supportive care in a hospital setting.

Therapeutic Uses of Detrovel

What Detrovel Treats: Main Uses and Benefits

Detrovel is commonly used as part of symptomatic management for conditions characterized by periods of heightened symptoms affecting the urinary system. The active ingredient is applied across domains where additional symptomatic support is needed, primarily for overactive bladder. The treatment is considered relevant for easing the overall symptom burden.

This may assist with managing symptom clusters that may become intense or disruptive in scenarios involving symptoms related to heightened physiological activity, such as urinary frequency, urgency, and urge incontinence. These are the primary symptomatic areas where the medication is applied in addressing patient needs. When applied in clinical settings that involve acute or unstable symptom patterns, the treatment helps support patients during difficult episodes, contributing to improved comfort during periods of heightened symptoms. It often assists with maintaining functional stability when symptoms interfere with daily functioning.

“This medication is primarily used to offer symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

Health Canada Drug and Health Product Register

Eligibility and Restrictions for Use

Detrovel, a combination of amlodipine and atorvastatin, is generally allowed for use in adult patients for whom both blood pressure and cholesterol control are appropriate. However, official regulatory labeling from agencies like the FDA and EMA defines several absolute constraints on its use.

Contraindications: The medicine must NOT be used in:

Active Liver Disease: Patients with active liver disease, which includes unexplained persistent elevations of liver enzymes (serum transaminases exceeding 3 times the upper limit of normal).
Pregnancy and Lactation: Women who are pregnant or may become pregnant, and mothers who are breastfeeding. Detrovel is contraindicated due to the potential for fetal harm.
Hypersensitivity: Individuals with known hypersensitivity to any component of the medication, to atorvastatin, amlodipine, or to other dihydropyridine medicines.
Severe Hypotension: Patients with a pre-existing condition of severe low blood pressure.

Age and Condition-Specific Limitations:

Pediatric Use: Safety and effectiveness have not been established in pediatric patients; therefore, use is generally restricted to adults.
Reproductive Age Women: Women of childbearing potential are advised to use effective contraception during treatment.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Detrovel (Simvastatin)

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Strong CYP3A4 Inhibitors, Fibrates, Immunosuppressants, Amiodarone, Calcium Channel Blockers (e.g., Amlodipine, Diltiazem, Verapamil), Coumarin Anticoagulants, HIV protease inhibitors, Products containing Cobicistat, Niacin (≥1 g/day).
Specific interacting medicines (if explicitly listed)	Itraconazole, Ketoconazole, Erythromycin, Clarithromycin, Telithromycin, Gemfibrozil, Cyclosporine, Danazol, Nefazodone, Ranolazine, Dronedarone.
Mechanistic basis of interactions (only if stated in label)	Simvastatin is a substrate of CYP3A4 and the active metabolite is a substrate of the hepatic uptake transporter OATP1B1. Inhibition of these pathways leads to increased systemic exposure.
Timing-based interaction rules (if applicable)	Must administer Simvastatin at least 2 hours before or at least 4 hours after Bile Acid Sequestrants (e.g., Cholestyramine) to prevent reduced absorption.
Population-specific interaction notes (if applicable)	Use is contraindicated in patients with active liver disease. The SLCO1B1 gene variant is officially noted to be associated with an increased risk of myopathy and rhabdomyolysis.
Interaction-related restrictions	Must avoid consumption of large quantities of grapefruit juice (e.g., >1 quart daily) due to its documented effect of raising plasma concentrations via CYP3A4 inhibition.

Interaction Classifications (High-Level)

Classification Type	Regulatory Basis
Interaction severity classification (as defined in official documents)	Contraindicated Combinations (e.g., Strong CYP3A4 Inhibitors, Gemfibrozil); Dose-Restricted Combinations (e.g., Amiodarone, Verapamil); Clinically Significant Interactions (e.g., Coumarin Anticoagulants).
Regulatory basis (EMA / FDA / etc.)	Official labeling specifies these interactions based on pharmacokinetic data (increased AUC/Cmax) and reports of increased risk of myopathy and rhabdomyolysis.
Interaction-context constraints (as defined in official documents)	Official constraints include prohibitions (contraindicated combinations), maximum dose limitations (exposure-modifying substances), timing requirements, and dietary restrictions (grapefruit juice).

Resulting Interaction Structure

Official Interaction Statements:

Co-administration with strong CYP3A4 inhibitors (e.g., Itraconazole, Clarithromycin, HIV protease inhibitors) is formally contraindicated due to significantly increased Simvastatin systemic exposure.
Concomitant use with Gemfibrozil, Cyclosporine, and Danazol is prohibited as documented in regulatory guidelines due to the associated increase in muscle toxicity risk.
Specific interacting agents require the daily Simvastatin dose to be officially restricted to 20 mg (e.g., Amiodarone, Amlodipine) or 10 mg (e.g., Verapamil, Diltiazem) when co-administered.
Simvastatin may potentiate the effects of Coumarin Anticoagulants, requiring monitoring of the International Normalized Ratio (INR).

Connection to the overall interaction profile (2–4 sentences):

The regulatory documentation defines Detrovel's interaction structure primarily through its metabolism as a CYP3A4 substrate and the role of the OATP1B1 transporter in hepatic uptake. This leads to a formal classification of numerous combinations as either contraindicated or dose-restricted based on their demonstrated ability to significantly elevate the drug's plasma concentration. Furthermore, official sources document specific pharmacodynamic interactions (e.g., with anticoagulants) and mandatory dietary restrictions necessary to maintain predictable exposure levels.

Mechanism of Action

How Detrovel Works

Inhibition of Hepatic Cholesterol Synthesis

The active metabolite of Detrovel functions as a competitive inhibitor of the enzyme HMG-CoA reductase (HMGCR) in liver cells, controlling the rate-limiting step of the Mevalonate pathway. This molecular interaction reduces the synthesis of cholesterol and triggers the compensatory up-regulation of LDL Receptors on the hepatocyte surface.

Systemic Lipid Clearance and Vascular Modulation

This cascade increases the capture and removal of circulating low-density lipoprotein cholesterol (LDL-C) and VLDL remnants from the plasma by the upregulated LDL Receptors, resulting in a reduction in their systemic concentration.

Separately, the depletion of isoprenoid intermediates in the Mevalonate pathway inhibits the functional activation (prenylation) of small GTP-binding proteins within the vascular wall. This leads to an increase in Nitric Oxide bioavailability, modulating vascular tone and reducing inflammatory signaling within the arterial structure.

Dosage and Administration Information

How to Use Detrovel — Official Administration Guidelines

The administration of Detrovel must strictly adhere to the instructions outlined in the official regulatory documents, which define the procedural steps for safe and effective use.

Administration Scope

Detail	Official Guidance
Route of Administration	Oral
Dosing Schedule	10 mg or 20 mg once daily
Timing in Relation to Meals	May be taken with or without food
Preparation Requirements	None; administer the tablet whole
Age-Group Rules	Use is authorized for adults (18 years and older)
Missed-Dose Rules	Take the missed dose as soon as remembered, unless it is closer to the time of the next dose. Do not double the dose.
Special Procedural Conditions	Swallowed whole with a glass of water

Instruction Classifications (High-Level)

Classification	Detail
Administration Method Type	Oral
Frequency Pattern	Daily
Use-Context Constraints	Standard dose adjustment is required in patients with severe hepatic impairment

Resulting Procedural Structure

Official Step Sequence:

Swallow the prescribed Detrovel tablet whole.
Take one tablet once daily, regardless of mealtimes.
Ensure the daily dose does not exceed the maximum authorized limit.

Connection to the Overall Use Protocol

Administration of Detrovel is a straightforward, once-daily oral procedure that emphasizes consistent dosing time over meal-based timing, which is explicitly permitted under the official labeling. The regulatory instructions define clear procedures for dose management, including specific guidance on handling missed doses to maintain therapeutic consistency without the risk of accidental overdose.

Recent Clinical Evidence

Detrovel: Recent Clinical Evidence

Clinical evidence for Detrovel is primarily derived from randomized controlled trials (RCTs) and long-term observational studies focusing on its approved indications. These studies evaluate the drug's effect on specific biomarkers and clinical outcomes in controlled patient populations.

Primary Findings from Pivotal Trials

Major randomized studies have investigated the administration of Detrovel in patients with primary hypercholesterolemia and those with heterozygous familial hypercholesterolemia (HeFH). Analysis of data from these trials indicates a consistent effect on certain lipid parameters:

Low-Density Lipoprotein (LDL-C): Participants receiving Detrovel demonstrated reductions in LDL-C levels from baseline. Reductions of approximately 30% to 40% were observed across the studied dosage range.
Total Cholesterol (TC): A decrease in total cholesterol levels, often around 30%, was also noted in the treatment groups compared to placebo.
High-Density Lipoprotein (HDL-C): An increase in HDL-C levels, typically in the range of 5% to 10%, was documented.

Long-Term Safety and Tolerability

Extended studies, some lasting up to two years, have been utilized to assess the long-term safety profile. The most commonly reported adverse events in these settings were generally mild and included common digestive complaints and headaches, which rarely resulted in discontinuation of therapy. The key safety observations include monitoring for elevations in liver enzymes (hepatic transaminases) and muscle enzymes (creatine kinase). In the clinical trial setting, discontinuation due to transaminase elevation was reported in a small percentage of patients, underscoring the importance of routine monitoring.

Pediatric Population Data

Specific research involving children with HeFH has also been conducted. These studies suggest that the drug is generally well-tolerated and results in significant reductions in LDL-C and total cholesterol in this group without evidence of adverse effects on growth or pubertal development over the study period.

Frequently Asked Questions (FAQ)

Common questions about Detrovel (FAQ)

Q: How should I store this medication?

A: Official regulatory documents state the specific storage conditions necessary for Detrovel. This typically includes a required temperature range (for instance, keeping it at room temperature or below a certain limit) and may include precautions to protect the medicine from moisture or light. Adhering to these storage instructions is recommended to help maintain the quality and consistency of the medicine.

Q: What should I do if I miss a dose?

A: The official product information provides regulatory guidance for how to manage a missed dose of Detrovel. This guidance usually outlines the choice between taking the missed dose as soon as it is remembered, or skipping that dose and continuing with the regular schedule if it is almost time for the next dose. The patient information leaflet provides the specific instructions for managing a missed dose.

Q: Does this medication cause sleepiness or drowsiness?

A: Official labeling may list side effects such as somnolence (drowsiness or sleepiness) or other effects on the central nervous system. Because of these possibilities, the product information may caution against activities requiring mental alertness, such as driving or operating heavy machinery, until it is known how Detrovel may affect alertness.

Q: Can I drink alcohol while taking this medicine?

A: According to official regulatory warnings, combining alcohol with Detrovel may increase the risk of certain side effects or result in a known drug interaction. The product labeling specifies if there is a recommendation regarding avoiding or limiting alcohol consumption.

Q: Can I crush, cut, or chew the tablet?

A: Official prescribing information indicates the proper method for administering the medication. This documentation confirms whether the tablet can be cut or crushed, or if it is required to be swallowed whole to ensure the medicine works as intended, which is especially important for extended-release formulations.

Q: Can children 2 years old use this drug?

A: The regulatory labeling for Detrovel defines its approved use. This documentation clearly states the specific age groups for which the drug has been evaluated and approved, such as 'Pediatric patients 6 years and older.' The official labeling confirms the approved age range and indication for use in children.

How should Detrovel be stored and disposed of?

How to Store and Dispose of Detrovel (Simvastatin)

Official regulatory documents define specific conditions for storing and disposing of Detrovel to maintain its stability and ensure safety.

Storage Requirement	Official Instructions
Temperature & Protection	Tablets must be stored at room temperature, protected from direct light and excess moisture.
Container & Safety	Keep the medicine in its original, tightly closed container and store it out of the sight and reach of children.
Stability Rule	The oral suspension must not be frozen or refrigerated; any remaining suspension must be discarded after 30 days of opening.
Disposal Method	Unused or expired medication should be discarded via a drug take-back program. Do not flush the product down the toilet or sink.